Page 4 - Pharma Mar News Today

Spanish pharmaceutical group PharmaMar posted a 32% drop in annual net profit on Monday after the company recorded its best ever results in 2020 thanks to unprecedented growth in its oncology drugs... | February 28, 2022

Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results Continued Zepzelca Growth Across Second-Line SCLC Setting Xywav in Idiopathic Hypersomnia Granted FDA Priority Review and an August 12, 2021, PDUFA Target Action Date On Track to Close Acquisition of GW Pharmaceuticals plc in Early May, Creating an Innovative, High-Growth, Global Biopharma Leader Secured $5.35 Billion Financing Including $1.5 Billion Senior Secured Notes in Connection with GW Acquisition 23% of Revenue from Rec...

News TECNALIA ranked third in the list of Spanish organisations that applied for the most European patents in 2020 7 April 2021 TECNALIA has a portfolio of 192 patent families (783 patents) and 13 investee companies, which create 207 direct jobs. For the fifth consecutive year, TECNALIA was once again one of the top organisations in Spain in terms of the number of applications for European patents (click here for the historical record). Specifically, TECNALIA came in in third place with 17 Euro...

La farmacéutica española PharmaMar va a realizar un ensayo clínico de fase III con un compuesto para la enfermedad de ojo seco tras recibir la autorización de las autoridades de Estados Unidos.

FDA Breakthrough Therapy Designation in MAGE-A4 expressing patients. The Synovial Sarcoma market is expected to show positive growth, mainly ascribed to the increased prevalence and the anticipated launch of novel therapies, such as Anlotinib, ADP-A2M4, For further information on Market Impact by Therapies, visit: Synovial Sarcoma, also known as malignant synovioma, can originate from different soft tissue types, such as muscle or ligaments. It is a high-grade tumor and spreads to distant si...

PharmaMar sube en el Ibex 35 tras anunciar que invertirá 6 millones de euros en la ampliación de sus instalaciones de Colmenar Viejo con el fin de afrontar “sus nuevos retos empresariales y las futuras exigencias del mercado”.

Coronvirus treatment: Plitidepsin, according to the researchers, should be considered for clinical trials based on its in vivo study results. Plitidepsin aka Aplidin is owned by Spanish pharmaceutical company Pharma Mar

People may get to choose the time, vaccination centre for Covid shots Members of the general public in the priority groups may be able to choose the vaccination centre and the time for getting their shots, according to a report in the Hindustan Times citing officials with knowledge of the matter. This group includes about 270 million people above the age of 50 as well as younger people with comorbidities associated with higher risk from Covid-19. As of Monday this week, India has vaccinated 2...

A research team at UCSF has landed on a potential game-changing treatment for COVID-19, though it is a cancer drug made by a Spanish firm that is not yet approved for any uses in the United States.

The UCSF-led team racing to find a COVID cure may have found a promising candidate FacebookTwitterEmail 1of5 Aplidium albicans is a marine invertebrate that lives off the shores of a tiny, uninhabited island in the Mediterranean Sea.Courtesy of Pharma MarShow MoreShow Less 2of5 Aplidium albicans — a type of “sea squirt” found near Es Vedrà off the coast of Ibiza. (Photo by Andres Iglesias/Getty Images)Andres Iglesias / Getty ImagesShow MoreShow Less 3of5 Aplidium albicans — a type of ...